<DOC>
	<DOCNO>NCT00968435</DOCNO>
	<brief_summary>The purpose study determine effectiveness treatment bevacizumab + cisplatin + cetuximab + IMRT . The doctor wish monitor patient 2 year completion study treatment determine cancer-free time . They also want evaluate side effect patient experience treatment regimen .</brief_summary>
	<brief_title>Bevacizumab , Cetuximab , Cisplatin With IMRT ( Intensity-Modulated Radiation Therapy ) Patients With Stage III/IV Head Neck Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Stage III/IV HNSCC without distant metastasis . Patients stage II squamous cell carcinoma hypopharynx also eligible Adequate renal function , serum creatinine ≤ 1.5 mg/dL . Patients serum creatinine &gt; 1.5 mg/dL may eligible calculated creatinine clearance &gt; = 55 ml/min Cockcroft Gault equation ( 24hour urine collection ) . Age &gt; = 18 year . Karnofsky performance status &gt; = 70 % Adequate bone marrow function : absolute neutrophil count &gt; = 1,500/ platelet &gt; = 100,000/ul , hemoglobin &gt; = 9 gm/dl Adequate hepatic function : Total bilirubin ≤ 1.5 X ULN ( patient Gilbert 's syndrome cause hyperbilirubinemia may eligible total bilirubin ≤ 2.5 X ULN ) , aspartate aminotransferase ( AST ) ≤ 2.5 X ULN , alanine aminotransferase ( ALT ) ≤ 2.5 X ULN , alkaline phosphatase ≤ 2.5 X ULN . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Patients must ability understand willingness sign write informed consent document . Prior radiation therapy HNSCC Prior treatment HNSCC bevacizumab agent specifically target VEGF Prior treatment HNSCC cetuximab agent specifically target EGFR Other active malignancy , indolent malignancy , investigator determines unlikely interfere treatment efficacy analysis . For example , patient nonmelanoma skin cancer , situ carcinoma cervix , prostate cancer within current biochemical ( PSA ) radiologic evidence disease may enroll . Patients nasopharyngeal carcinoma Patients receive amifostine part radiation treatment plan Patients skin breakdown/ulceration ( CTCAE version 3.0 , grade 2 high ) . Patients hear loss require hear aid intervention ( i.e . interfere clinically significant way activity daily live ) . Patients multifocal peripheral sensory alteration paresthesias ( include tingle ) interfere function , per patient report ( example : activity daily live ) . Any prior document history transient ischemic attack ( TIA ) cerebrovascular accident ( CVA ) History unstable angina myocardial infarction ( MI ) within last year . Urine protein : creatinine ( UPC ) ratio &gt; = 1.0 screening . A random urine sample collect . Total protein ( mg/dL ) spot creatinine ( mg/dL ) order sample . The UPC ratio calculate result test . International normalized ratio ( INR ) &gt; 1.5 activate partial thromboplastin time ( aPTT ) &gt; 1.5 X upper limit normal ( ULN ) Current use warfarin , current use heparin lowmolecular weight heparin , chronic daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function . Patients gross hemoptysis hematemesis ( define bright red blood 1 teaspoon ) within 28 day prior Day 0 protocol treatment exclude trial . Patients incidental blood mixed phlegm exclude . Esophageal varix , nonhealing ulcer , wound , bone fracture exclusion criterion . However , patient skin breakdown overlie malignant neck lymphadenopathy may eligible , discretion investigator . Anatomic lesion increase risk serious hemorrhage , encasement invasion major blood vessel primary tumor and/or involve lymph node Blood pressure &gt; 150/100 mmHg New York Heart Association ( NYHA ) Grade II great congestive heart failure . Clinically significant peripheral vascular disease History bleed diathesis hemorrhagic disorder , coagulopathy . Major surgical procedure significant traumatic injury within 28 day prior treatment bevacizumab Core biopsy within 7 day prior treatment bevacizumab . Minor surgical procedure fine needle aspiration placement percutaneous gastrostomy tube ( PEG ) less 7 day prior treatment bevacizumab History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior enrollment . Inability comply study and/or followup procedure Women pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>cisplatin</keyword>
	<keyword>cetuximab</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>Phase II</keyword>
	<keyword>09-083</keyword>
</DOC>